Jeffrey D Ahlers

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines
    Jeffrey D Ahlers
    Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 USA
    Curr Mol Med 3:285-301. 2003
  2. doi request reprint Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS
    Jeffrey D Ahlers
    NIAID, NIH, Bethesda, MD 20817, USA
    Trends Immunol 31:120-30. 2010
  3. ncbi request reprint Strategies for optimizing targeting and delivery of mucosal HIV vaccines
    Jeffrey D Ahlers
    Division of AIDS, NIAID, NIH, Rockville, MD 20817, USA
    Eur J Immunol 39:2657-69. 2009
  4. ncbi request reprint New paradigms for generating effective CD8+ T cell responses against HIV-1/AIDS
    Jeffrey D Ahlers
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20817, USA
    Discov Med 9:528-37. 2010
  5. doi request reprint Strategies for recruiting and targeting dendritic cells for optimizing HIV vaccines
    Jeffrey D Ahlers
    Division of AIDS, NIAID, National Institutes of Health, 6700 Rockledge Dr, Bethesda, MD 20817, USA
    Trends Mol Med 15:263-74. 2009
  6. doi request reprint Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization
    Igor M Belyakov
    Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA Midwest Research Institute, Frederick, MD 21702, USA
    Virology 381:106-15. 2008
  7. ncbi request reprint Selective induction of high avidity CTL by altering the balance of signals from APC
    SangKon Oh
    Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 170:2523-30. 2003
  8. pmc Memories that last forever: strategies for optimizing vaccine T-cell memory
    Jeffrey D Ahlers
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA
    Blood 115:1678-89. 2010
  9. ncbi request reprint Role of alpha3 domain of class I MHC molecules in the activation of high- and low-avidity CD8+ CTLs
    Igor M Belyakov
    Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Int Immunol 19:1413-20. 2007
  10. pmc Progress on new vaccine strategies against chronic viral infections
    Jay A Berzofsky
    Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, The Center for Cancer Research, National Cancer Institute NIH, 10 Center Drive, Bethesda, MD 20892, USA
    J Clin Invest 114:450-62. 2004

Detail Information

Publications17

  1. ncbi request reprint Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines
    Jeffrey D Ahlers
    Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 USA
    Curr Mol Med 3:285-301. 2003
    ..In this review we will discuss the application and delivery of cytokines, costimulatory molecules, and chemokines toward improving current vaccine strategies...
  2. doi request reprint Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS
    Jeffrey D Ahlers
    NIAID, NIH, Bethesda, MD 20817, USA
    Trends Immunol 31:120-30. 2010
    ..Here, we discuss qualitative parameters of the CD8(+) CTL response and mechanisms operative in the control of persistent virus infections and suggest new strategies for design and delivery of HIV vaccines...
  3. ncbi request reprint Strategies for optimizing targeting and delivery of mucosal HIV vaccines
    Jeffrey D Ahlers
    Division of AIDS, NIAID, NIH, Rockville, MD 20817, USA
    Eur J Immunol 39:2657-69. 2009
    ..Here, we discuss novel vaccine strategies and adjuvants for optimizing mucosal delivery of HIV vaccines...
  4. ncbi request reprint New paradigms for generating effective CD8+ T cell responses against HIV-1/AIDS
    Jeffrey D Ahlers
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20817, USA
    Discov Med 9:528-37. 2010
    ..Here, we highlight factors considered essential for effective HIV-1 vaccine CD8+ T cell responses: vaccine antigens, quality, magnitude and breadth, mucosal targeting, and formation of CD8+ T cell mucosal memory...
  5. doi request reprint Strategies for recruiting and targeting dendritic cells for optimizing HIV vaccines
    Jeffrey D Ahlers
    Division of AIDS, NIAID, National Institutes of Health, 6700 Rockledge Dr, Bethesda, MD 20817, USA
    Trends Mol Med 15:263-74. 2009
    ..Here, we discuss current vaccine strategies for optimizing the induction of immune responses by the recruitment of DCs and the targeting of vaccine antigens to DCs...
  6. doi request reprint Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization
    Igor M Belyakov
    Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA Midwest Research Institute, Frederick, MD 21702, USA
    Virology 381:106-15. 2008
    ....
  7. ncbi request reprint Selective induction of high avidity CTL by altering the balance of signals from APC
    SangKon Oh
    Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 170:2523-30. 2003
    ..Our data also suggested that dendritic cells play an important role in induction of high avidity CD8(+) CTL in vivo. This strategy to selectively induce higher avidity CTL may lead to more effective vaccines for viruses and cancer...
  8. pmc Memories that last forever: strategies for optimizing vaccine T-cell memory
    Jeffrey D Ahlers
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA
    Blood 115:1678-89. 2010
    ..In this review we will focus on discussing mechanisms involved in T-cell memory and provide promising new approaches toward expanding current vaccine strategies to enhance antiviral memory...
  9. ncbi request reprint Role of alpha3 domain of class I MHC molecules in the activation of high- and low-avidity CD8+ CTLs
    Igor M Belyakov
    Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Int Immunol 19:1413-20. 2007
    ..Thus, low-avidity CTL may not be able to take advantage of the interaction between CD8 and the alpha3 domain of non-presenting class I MHC molecules, perhaps because of a shorter dwell time for the TCR-MHC interaction...
  10. pmc Progress on new vaccine strategies against chronic viral infections
    Jay A Berzofsky
    Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, The Center for Cancer Research, National Cancer Institute NIH, 10 Center Drive, Bethesda, MD 20892, USA
    J Clin Invest 114:450-62. 2004
    ..We also explore novel strategies for increasing the immunogenicity and efficacy of vaccines...
  11. pmc Progress on new vaccine strategies for the immunotherapy and prevention of cancer
    Jay A Berzofsky
    Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    J Clin Invest 113:1515-25. 2004
    ..This review examines the fundamental immunologic advances and the novel vaccine strategies arising from these advances, as well as the early clinical trials studying new approaches to treat or prevent cancer...
  12. pmc Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells
    Igor M Belyakov
    Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1578, USA
    J Clin Invest 113:998-1007. 2004
    ..These results and previous clinical trial results support the observation that TCI is a safe and effective strategy for inducing strong mucosal antibody and CTL responses...
  13. pmc Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses
    Igor M Belyakov
    Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 100:9458-63. 2003
    ..These properties, shared with the existing smallpox vaccine, provide a basis for further evaluation of these replication-deficient vaccinia viruses as safer vaccines against smallpox or against complications from vaccinia virus...
  14. doi request reprint Molecular pathways regulating CD4(+) T cell differentiation, anergy and memory with implications for vaccines
    Jeffrey D Ahlers
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20817, USA
    Trends Mol Med 16:478-91. 2010
    ..Here, we discuss lineage instructive programs that regulate CD4(+) T cell differentiation and memory and how to translate this knowledge into vaccines and immunotherapies that promote protective immune responses...
  15. ncbi request reprint Mucosal AIDS vaccines: current status and future directions
    Igor M Belyakov
    Molecular Immunogenetics and Vaccine Research, Section, Vaccine Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA
    Expert Rev Vaccines 3:S65-73. 2004
    ....
  16. pmc A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L
    Jeffrey D Ahlers
    Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 99:13020-5. 2002
    ..These results argue for a push-pull approach to maximize vaccine efficacy, especially for HIV and cancer...
  17. ncbi request reprint Assessing CD4+ helper T-lymphocyte responses by lymphoproliferation
    Isabella A Quakyi
    Department of Biology, Georgetown University, Washington, DC, USA
    Methods Mol Med 72:369-83. 2002